Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016" report to their offering.

Focal Segmental glomerulosclerosis is a rare disease that attacks the kidney's filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. Symptoms include proteinuria, edema, high cholesterol, high blood pressure and poor appetite. Risk factors include infection, obesity, sickle cell disease and reflux nephropathy. Treatment includes antibiotics, vitamin D supplements, and immunosuppressive drugs.

This report provides comprehensive information on the therapeutic development for Focal Segmental Glomerulosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Focal Segmental Glomerulosclerosis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Mentioned:

  • Complexa Inc
  • Dimerix Bioscience Pty Ltd
  • GlaxoSmithKline Plc
  • Retrophin Inc
  • Shire Plc
  • Variant Pharmaceuticals Inc

Key Topics Covered:

  1. Introduction
  2. Focal Segmental Glomerulosclerosis Overview
  3. Therapeutics Development
  4. Pipeline Products for Focal Segmental Glomerulosclerosis - Overview
  5. Pipeline Products for Focal Segmental Glomerulosclerosis - Comparative Analysis
  6. Focal Segmental Glomerulosclerosis - Therapeutics under Development by Companies
  7. Focal Segmental Glomerulosclerosis - Therapeutics under Investigation by Universities/Institutes
  8. Focal Segmental Glomerulosclerosis - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Focal Segmental Glomerulosclerosis - Products under Development by Companies
  13. Focal Segmental Glomerulosclerosis - Products under Investigation by Universities/Institutes
  14. Focal Segmental Glomerulosclerosis - Companies Involved in Therapeutics Development

For more information about this report visit http://www.researchandmarkets.com/research/q4f7k9/focal_segmental

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Liver and Kidney Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Liver and Kidney Disorders Drugs